Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioLineRx has reported positive results from pre-clinical trials, which demonstrated that BL-1021 was safe and effective in pre-clinical testing for the treatment of neuropathic pain.
Subscribe to our email newsletter
In pre-clinical trials, BL-1021 showed a significant reduction in symptoms of neuropathic pain with reduced side effects. The molecule was given orally and in all cases was found to be superior to available treatments due to its increased efficacy and minimal side effects. Furthermore, the experiments demonstrated that BL-1021 demonstrated potent analgesia drug without noticeable side effects of sedation and cardiac arrhythmias, which often plague other anti pain compounds.
BL-1021, an orally available small molecule for the treatment of neuropathic pain is being developed by BioLineRx under a worldwide exclusive license from Ramot at Tel Aviv University and Bar-Ilan Research and Development Company, the technology transfer arms of Tel Aviv University and Bar-Ilan University.
Morris Laster, CEO of BioLineRx, said: “We believe that BL-1021 has the potential to be a safe and effective drug for neuropathic pain, and we look forward to the initiation of the clinical trial program for this compound in 2008.”